Overview
- The company filed six lawsuits that name Aesthetic Envy, Astra LLC, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide Co., which Lilly says sold or marketed unauthorized retatrutide products.
- Lilly filed the suits on Wednesday, Aug. 12, as the latest step in a campaign that has already referred more than 200 suspected sellers to the FDA, DOJ, state attorneys general and other authorities.
- Retatrutide remains investigational in Phase 3 trials and has not been approved for human use, though Lilly has started a limited expanded access program and plans to pursue regulatory approval in early 2027.
- The company and regulators warn that black‑market products are unverified and risky, and U.S. Customs reported a sharp rise in seizures with more than 1,400 GLP‑1 shipments and nearly 90,000 vials intercepted in July.
- Lilly is pressing social and e‑commerce platforms, payment processors and shippers to cut off the illicit trade because it says only coordinated action across companies and law enforcement can protect patients and the integrity of clinical research.